Avacta and Tempus Collaboration for AI-Driven Oncology
Avacta Group plc, also referred to as "Avacta" or "the Company," has embarked on an exciting venture with Tempus AI, Inc. This partnership focuses on leveraging artificial intelligence to propel drug development within oncology, aiming to enhance patient care and treatment precision.
Deep Data Insights for Enhanced Drug Development
The collaboration grants Avacta access to Tempus' extensive multimodal datasets. This rich resource encompasses primary tumor samples and clinical data from over 200,000 patients, which is crucial for analyzing various cancer forms.
Utilizing these insights, Avacta aims to deepen its understanding of the tumor microenvironment and the activity of fibroblast activation protein (FAP). This essential analysis will provide the groundwork for the enhancement of Avacta’s remarkable pre|CISION® technology.
New Additions to the pre|CISION® Platform
Recently, Avacta has expanded its pre|CISION® platform, showcasing two new preclinical initiatives: AVA6103 and AVA7100. AVA6103 stands out as a cutting-edge peptide drug conjugate, which employs exatecan—a powerful topoisomerase I inhibitor. Its design aims to deliver potent anti-tumor effects directly to malignancies while sparing healthy tissue from harm. Meanwhile, AVA7100 represents a first-in-class Affimer® drug conjugate, specifically targeting cancers that exhibit diversified FAP expression levels.
Enhancing Cancer Treatment Personalization
This dynamic partnership is set to amplify Avacta's efforts in pinpointing the wider patient population eligible for clinical programs. By collaborating with Tempus' specialized computational biology and analytical skillsets, Avacta is positioned to heighten the efficacy of its cancer treatments.
Dr. Christina Coughlin, CEO of Avacta, emphasized the collaborative potential of this partnership, stating that a nuanced comprehension of tumor biology and FAP activity will significantly benefit their clinical pipeline. Avacta’s commitment to advancing personalized therapies aligns seamlessly with Tempus’ capabilities in data analysis, setting a promising trajectory for the future of cancer treatment.
AI's Role in Modern Medicine
This collaboration highlights a broader trend in modern medicine—using AI to foster innovative solutions in drug discovery and development. The integration of real-world data into clinical research not only aids in understanding which patient demographics respond best to specific treatments but also fast-tracks the drug development process.
Tempus’ Vision and Contributions
Tempus has built its identity around establishing one of the largest repositories of multimodal data in the world. The company's mission to make this data accessible and impactful aligns perfectly with Avacta’s goal of delivering groundbreaking therapies to patients grappling with cancer.
As stated by Dr. Kate Sasser, Chief Scientific Officer at Tempus, the partnership reflects a significant step towards achieving their shared vision—a transformation in how personalized medicine is approached. The synergy between both organizations catalyzes the development of innovative therapeutics aimed at offering new hope to patients.
About the pre|CISION® Platform
The pre|CISION® platform utilizes unique peptide drug conjugates designed to target FAP, prevalent in most solid tumors, thus allowing for a decrease in damaging side effects typically associated with conventional treatments. The platform employs the tumor microenvironment to liberate therapeutic agents directly where they are most needed.
Details on AVA6000 Program
Among the most promising initiatives is the AVA6000 program, which is currently undergoing Phase 1 studies as a modified doxorubicin conjugate. Early findings showcase improvements in safety profiles and preliminary signs of efficacy, distinguishing it from traditional doxorubicin treatment.
About Avacta Group plc
Avacta Group is a pioneering UK life sciences firm dedicated to enhancing healthcare outcomes with targeted cancer therapies. Their strong focus on innovation positions them at the forefront of biotech advancements, working assiduously to modify the landscape of cancer treatment through advanced technologies.
Frequently Asked Questions
What is the aim of the Avacta and Tempus collaboration?
The partnership focuses on utilizing AI and extensive datasets to improve precision in drug development for oncology treatments.
What are the new additions to Avacta's pre|CISION® platform?
Two new preclinical programs have been introduced: AVA6103, a peptide drug conjugate, and AVA7100, an Affimer® drug conjugate targeting varying FAP expressions in tumors.
How does AI contribute to modern oncology?
AI helps analyze real-world data to determine patient demographics that respond best to certain therapies, enhancing the drug development process.
What is the pre|CISION® platform?
It is a cutting-edge approach that utilizes targeted drug conjugates to directly attack tumors while minimizing damage to healthy tissue.
What is Avacta's lead program in drug development?
The lead program, AVA6000, is currently in Phase 1 trials, showing a promising safety profile compared to standard doxorubicin treatments.
